AstraZeneca's leading lung cancer drug, Tagrisso, accepted and granted priority review in the US
AstraZeneca’s supplemental new drug application (sNDA) for lead lung cancer drug Tagrisso (Osimertinib) in combination with chemotherapy has been accepted and granted priority review in the US.
